Dr. Dölen earned her M.D., Ph.D. at Brown University, and the Massachusetts Institute of Technology (MIT), and completed postdoctoral training in the Department of Psychiatry at Stanford University. Dr. Dölen is currently an Associate professor of Neuroscience and Neurology at the Johns Hopkins University, School of Medicine. Her laboratory has discovered a novel mechanism that could account for the broad range of therapeutic applications for which psychedelics are currently being tested. Specifically, the Dolen lab has discovered critical periods can be reopened with psychedelic drugs like MDMA (Nardou, et al Nature, 2019), LSD, psilocybin, ketamine, and ibogaine (Nardou et al, Nature in Press). Importantly, understanding psychedelics through this framework dramatically expands the scope of disorders that might benefit from adjunct therapy with psychedelics, an approach she has dubbed the PHATHOM project (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability, www.phathomproject.org).